Table I.
Serum CgA levels in patients with primary or advanced gastroenteropancreatic neuroendocrine neoplasms (n=73) using Kruskal-Wallis test.
| Variables | n | Median CgA level, ng/ml (range) | Z-value | P-value |
|---|---|---|---|---|
| Age, years | 0.998 | 0.319 | ||
| <54 | 33 | 155.64 (56.77–421.01) | ||
| ≥54 | 40 | 110.23 (57.46–213.29) | ||
| Sex | 0.000 | 1.000 | ||
| Male | 40 | 110.23 (58.18–300.28) | ||
| Female | 33 | 143.69 (56.77–326.93) | ||
| Tumour site | 19.681 | <0.001 | ||
| Stomach | 13 | 259.95 (112.73–1442.34) | ||
| Intestines | 28 | 57.665 (44.12–109.41) | ||
| Pancreas | 32 | 161.95 (102.24–367.14) | ||
| Grade | 3.359 | 0.186 | ||
| G1 | 17 | 105.09 (56.96–272.44) | ||
| G2 | 40 | 123 (49.17–287.94) | ||
| G3 | 16 | 178.5 (104.97–578.22) | ||
| Lesions | 2.260 | 0.024 | ||
| Primary | 38 | 146.71 (66.33–419.7) | ||
| Recurrent | 35 | 103.24 (45.5–186.43) | ||
| Metastasis | 0.743 | 0.458 | ||
| No | 14 | 125.93 (66.33–419.7) | ||
| Yes | 59 | 115.31 (53.59–293.96) | ||
| IHC (CgA) | 2.277 | 0.023 | ||
| − | 13 | 56.66 (34.04–94.78) | ||
| + | 47 | 155.64 (58.08–405.56) | ||
| IHC (CD56) | 0.398 | 0.690 | ||
| − | 5 | 108.35 (67.23–223.77) | ||
| + | 36 | 112.81 (56.29–415.18) | ||
| IHC (Syn) | 0.531 | 0.596 | ||
| − | 1 | −a | ||
| + | 61 | 115.31 (54.84–350.37) |
a
Interquartile ranges and median CgA level were unable to be obtained due to small needle biopsy samples. CgA, chromogranin A; IHC, immunohistochemistry; CD56, neural cell adhesion molecule 1; Syn, synaptophysin.